Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019 with Alexion Pharmaceuticals, Amgen, Celgene, F. Hoffmann- La Roche, GlaxoSmithKline & Incyte Dominating

News provided by

Research and Markets

20 Apr, 2015, 15:12 GMT

DUBLIN, Apr. 20, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/btskm6/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering.

Continue Reading
This image opens in the lightbox
600769
This image opens in the lightbox
Research and Markets

The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019

Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis.

This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.

Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price.

According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups.

Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population.

Key Vendors

  • Alexion Pharmaceuticals
  • Amgen
  • Celgene
  • F. Hoffmann- La Roche
  • GlaxoSmithKline
  • Incyte

Other Prominent Vendors

  • Cyclacel Pharmaceuticals
  • CTI Biopharma (Cell Therapeutics)
  • Eli Lilly
  • Gilead Sciences
  • Onconova Therapeutics
  • MebVax Therapeutics
  • Novartis
  • Sanofi
  • Shire Pharmaceuticals
  • S* Bio Pte

For more information visit http://www.researchandmarkets.com/research/btskm6/global_acquired

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net